American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 41-46, July 2003

Plasma homocysteine is elevated in patients with exfoliation syndrome

This study was presented in part at the Annual Meeting of the American Academy of Ophthalmology, Orlando, Florida, October 2002.

  • Roberto M Vessani, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA
  • ,
  • Robert Ritch, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA
    • Department of Ophthalmology, The New York Medical College, Valhalla, New York (R.R.), USA
    • Corresponding Author InformationInquiries to Robert Ritch, MD, Glaucoma Service, Department of Ophthalmology, The New York Eye and Ear Infirmary, 310 East 14th St, New York, NY 10003, USA; fax: (212) 420-8743
  • ,
  • Jeffrey M Liebmann, MD

      Affiliations

    • Department of Ophthalmology, New York University School of Medicine and the Manhattan Eye, Ear and Throat Hospital, New York, New York (J.M.L.), USA
  • ,
  • Mark Jofe, MD

      Affiliations

    • Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York (R.M.V., R.R., M.J.), USA

Accepted 3 January 2003.

Abstract 

Purpose

To compare plasma homocysteine concentrations among patients with exfoliation syndrome, exfoliative glaucoma, normal-tension glaucoma, and normal control subjects without vascular or inflammatory ocular disease or glaucoma.

Design

Cross-sectional study.

Methods

We tested 25 patients with exfoliation syndrome, 50 with exfoliative glaucoma, 25 with normal-tension glaucoma, and 24 control subjects. Fasting plasma homocysteine concentrations were measured by fluorescence polarization immunoassay. Patients using vitamin supplements or medications known to alter serum homocysteine were excluded.

Results

Homocysteine levels were higher in both exfoliation groups compared with controls (exfoliation syndrome: P = .003; exfoliative glaucoma: P = .009); levels in normal-tension glaucoma were higher than but not significantly different from those in controls (P = .2). Hyperhomocysteinemia was present in 16 of 25 (64%) exfoliation syndrome patients, 28 of 50 (56%) exfoliative glaucoma patients, 13 of 25 (52%) normal-tension glaucoma patients, and 7 of 24 (29.2%) controls (P = .005). Multiple logistic regression analyses comparing exfoliation syndrome and exfoliative glaucoma patients with controls indicated that elevated plasma homocysteine concentration was a significant risk factor for exfoliation syndrome, in both those patients (odds ratios per 1.0 μmol/l increase in plasma homocysteine concentrations = 1.47; 95% confidence interval [CI] = 1.08–2.0) and in exfoliative glaucoma patients (odds ratio = 1.3; 95% CI = 1.07–1.6). Although exfoliative glaucoma and normal-tension glaucoma patients were not signficantly different with respect to hyperhomocysteinemia, logistic regression modeling of exfoliative glaucoma vs normal-tension glaucoma patients showed that an increased homocysteine concentration was a significant risk factor for exfoliation syndrome in the presence of glaucoma (odds ratio per 1.0 μmol/l increase in homocysteine = 1.2, 95% CI = 1.0–1.4). These relationships were not affected by adjustment for potential confounding due to sex, history of hypertension, or other factors.

Conclusions

Elevated plasma homocysteine, a risk factor for cardiovascular disease, is more common in exfoliation syndrome and exfoliative glaucoma patients than healthy controls. Patients with exfoliation syndrome may benefit from measurement of homocysteine levels.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by an unrestricted grant from Pharmacia Corporation and by the Joseph and Barbara Cohen Research Fund of the New York Glaucoma Research Institute, New York, New York, and by an unrestricted grant from the Eye Bank for Sight Restoration, New York, New York.

PII: S0002-9394(03)00077-1

doi:10.1016/S0002-9394(03)00077-1

American Journal of Ophthalmology
Volume 136, Issue 1 , Pages 41-46, July 2003